The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 ...

After an impressive pre-season, the Honda rider feels the team are moving in the right direction though he is keeping his ...

Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...

AI accelerates drug development, cutting costs and boosting success rates. Discover how AI is reshaping the future of ...

The Floodlight MS app, used to track disease progression in people with multiple sclerosis, has been deemed cost-effective in ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

The record winning margin in the UAE is 1:01 held by Adam Yates, coincidentally ahead of his now-teammate Pogačar back in ...

Renal Function Test MarketThe global renal function test market is poised for steady growth, with revenue projected to reach USD 1,494.1 million by 2033, up from USD 871.3 million in 2023. With a ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...